Lonza has launched two new products to strengthen its offering for cell and gene therapy developers: TheraPEAK AmpliCell Cytokines and TheraPEAK 293-GT Medium. The additions address critical manufacturing requirements for immune cell expansion and adeno-associated virus (AAV) production, respectively.

Mammalian-derived cytokines target consistency in immune cell manufacturing

The AmpliCell Cytokines are produced using a mammalian expression system, engineered to deliver high biological activity through proper protein folding and glycosylation. This native-like structure distinguishes them from bacterial-derived alternatives, which cannot replicate the post-translational modifications essential for optimal biological function. The cytokines support expansion, activation and differentiation of immune cells whilst maintaining batch-to-batch consistency – a key consideration for translational applications moving from research through to GMP manufacturing environments.

“The introduction of AmpliCell Cytokines and the 293-GT Medium to our TheraPEAK Range greatly enhances our offering for cell and gene therapy customers, providing them with reliable solutions to support their drug development efforts,” said Mike Goetter, Head of Bioscience, Specialised Modalities at Lonza.

Chemically defined medium system optimised for AAV production

The 293-GT Medium represents a chemically defined, animal-origin-free system designed for AAV production in suspension HEK293 cells. The medium system offers compatibility with commercially available transfection reagents and AAV enhancers, whilst delivering strong AAV titres and supporting favourable full-to-empty capsid ratios. The drop-in-ready formulation allows integration into existing workflows without requiring extensive process modifications.

Regulatory track record supports clinical translation

The TheraPEAK product range has featured in more than 130 clinical trials globally and has been utilised in therapies that have secured regulatory approval. The expanded portfolio provides scalable, regulatory-ready solutions that span the development continuum from early discovery through clinical-stage manufacturing.

Both products address persistent challenges in cell and gene therapy production, where consistency, scalability and regulatory compliance remain critical determinants of commercial success.

For more information, visit: https://shorturl.at/g9Gsk
Digital issue: Please click here for more information